Fresh commentary on DENTSPLY SIRONA (XRAY) is drawing attention to weak constant currency revenue growth, falling earnings per share, and negative returns on capital. This is raising questions about how current plans are affecting long term profitability.

The recent weakness in constant currency revenue and returns on capital appears to be weighing on sentiment. The share price is down 7.97% over 30 days and the 1 year total shareholder return has fallen 35.30%. This points to fading momentum despite a modest 7 day share price rebound.

If you are reassessing your exposure to healthcare and looking for fresh ideas beyond this stock, it could be worth scanning 39 healthcare AI stocks for potential opportunities in adjacent niches.

With the stock down sharply over 1 and 5 years, yet trading at a discount to analyst targets and some estimates of intrinsic value, you need to ask whether this is a reset worth considering or if the market is already discounting future growth.

Most Popular Narrative: 77.9% Undervalued

According to the most followed narrative, DENTSPLY SIRONA's fair value of $45.50 sits far above the last close at $10.04, creating a wide valuation gap that rests on a very specific view of the business.

Dentsply Sirona is built for endurance. Its business model mirrors the dental industry itself: methodical, relationship-driven, and anchored in necessity. For investors, XRAY represents exposure to healthcare demand that persists across cycles. It may never dominate headlines, but its relevance is quietly reinforced every time a patient sits in a dental chair.

The fair value hinges on long replacement cycles, recurring consumables, and the expectation that practice level economics keep cash flows resilient. Want to see how that all feeds into revenue, margins, and future profitability projections without the market noise?

Result: Fair Value of $45.50 (UNDERVALUED)

However, this endurance story faces clear risks. The recent 35.30% 1 year total return decline and the current net loss of US$628.0 million are weighing on confidence.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If the sentiment in this article feels cautious, that is intentional. You should move quickly to check the upside case for yourself by reviewing the 3 key rewards.

Looking for more investment ideas?

If XRAY has you rethinking your healthcare exposure, do not stop there. Broaden your watchlist with targeted stock ideas that match what you care about most.

• Target income first and scan 9 dividend fortresses that focus on higher yields with an eye on stability.
• Spot potential value gaps by reviewing 48 high quality undervalued stocks that combine quality fundamentals with pricing that some investors may overlook.
• Prioritise resilience by filtering through 63 resilient stocks with low risk scores so you do not miss companies with steadier risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.